MedPath

Abnoba GmbH

Abnoba GmbH logo
🇩🇪Germany
Ownership
Private
Employees
11
Market Cap
-
Website
http://www.abnoba.de

Clinical Trials

5

Active:2
Completed:2

Trial Phases

3 Phases

Phase 1:3
Phase 3:1
Phase 4:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 3
1 (20.0%)
Phase 4
1 (20.0%)

Therapeutic Instillation of Mistletoe

Phase 3
Active, not recruiting
Conditions
Superficial Bladder Cancer
Interventions
Drug: abnobaVISCUM 900
First Posted Date
2014-04-08
Last Posted Date
2025-07-23
Lead Sponsor
Abnoba Gmbh
Target Recruit Count
548
Registration Number
NCT02106572
Locations
🇪🇬

Theodor Bilharz Research Institute, Giza, Egypt

🇩🇪

Clinic of Urology of the University Hospital of Essen, Essen, Germany

🇩🇪

Urologische Gemeinschaftspraxis, Heinsberg, Germany

and more 2 locations

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Phase 1
Completed
Conditions
Superficial Bladder Cancer
Interventions
Drug: abnobaVISCUM Fraxini
First Posted Date
2013-12-10
Last Posted Date
2015-05-06
Lead Sponsor
Abnoba Gmbh
Target Recruit Count
37
Registration Number
NCT02007005
Locations
🇪🇬

Theodor Bilharz Research Institute, Giza, Egypt

🇩🇪

Clinic of Urology of the University Hospital of Essen, Essen, Germany

RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients

Phase 4
Completed
Conditions
Gastric Cancer
Interventions
Drug: mistletoe extract
First Posted Date
2011-07-25
Last Posted Date
2012-11-07
Lead Sponsor
Abnoba Gmbh
Target Recruit Count
32
Registration Number
NCT01401075
Locations
🇰🇷

ASAN Medical Center, Seoul, Korea, Republic of

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.